Surmodics’ (SRDX) “Hold” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their hold rating on shares of Surmodics (NASDAQ:SRDX) in a research note released on Thursday,Benzinga reports.

Separately, StockNews.com began coverage on Surmodics in a research report on Thursday. They set a “hold” rating on the stock. Five analysts have rated the stock with a hold rating, According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $50.00.

Surmodics Stock Up 0.2 %

Shares of Surmodics stock traded up $0.06 during trading on Thursday, reaching $38.46. The company had a trading volume of 118,959 shares, compared to its average volume of 230,828. The firm’s fifty day moving average is $38.60 and its 200-day moving average is $38.60. Surmodics has a fifty-two week low of $25.17 and a fifty-two week high of $42.44. The company has a market cap of $548.82 million, a price-to-earnings ratio of -47.41 and a beta of 1.20. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98.

Institutional Trading of Surmodics

Institutional investors and hedge funds have recently made changes to their positions in the business. Quest Partners LLC increased its stake in Surmodics by 107,100.0% in the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after buying an additional 1,071 shares during the last quarter. Hardin Capital Partners LLC bought a new stake in shares of Surmodics during the second quarter worth $206,000. SG Americas Securities LLC boosted its position in Surmodics by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 5,138 shares of the company’s stock worth $151,000 after buying an additional 660 shares during the period. The Manufacturers Life Insurance Company bought a new stake in shares of Surmodics in the 2nd quarter valued at about $229,000. Finally, Lazard Asset Management LLC raised its holdings in Surmodics by 13.4% during the 1st quarter. Lazard Asset Management LLC now owns 5,679 shares of the company’s stock worth $166,000 after purchasing an additional 673 shares during the last quarter. Institutional investors own 96.63% of the company’s stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).